CoChat

Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force

Open access
Kaye, Jeffrey, Aisen, P., Amariglio, R., Au, R., Ballard, C., Carrillo, M., Fillit, H., Iwatsubo, T., Jimenez-Maggiora, G., Lovestone, S., Natanegara, F., Papp, K., Soto, M.E., Weiner, M., Vellas, B. · 2021 · The Journal of Prevention of Alzheimer's Disease
Cited by 41

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

The 2020 COVID-19 pandemic has disrupted Alzheimer's disease (AD) clinical studies worldwide. Digital technologies may help minimize disruptions by enabling remote assessment of subtle cognitive and functional changes over the course of the disease. The EU/US Clinical Trials in Alzheimer's Disease (CTAD) Task Force met virtually in November 2020 to explore the opportunities and challenges associated with the use of digital technologies in AD clinical research. While recognizing the potential of digital tools to accelerate clinical trials, improve the engagement of diverse populations, capture clinically meaningful data, and lower costs, questions remain regarding the stability, validity, generalizability, and reproducibility of digital data. Substantial concerns also exist regarding regulatory acceptance and privacy. Nonetheless, the Task Force supported further exploration of digital technologies through collaboration and data sharing, noting the need for standardization of digital readouts. They also concluded that while it may be premature to employ remote assessments for trials of novel experimental medications, remote studies of non-invasive, multi-domain approaches may be feasible at this time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14283/jpad.2021.36

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 41

Metadata

Authors
Kaye, J., Aisen, P., Amariglio, R., Au, R., Ballard, C., Carrillo, M., Fillit, H., Iwatsubo, T., Jimenez-Maggiora, G., Lovestone, S., Natanegara, F., Papp, K., Soto, M. E., Weiner, M., & Vellas, B.
Venue
The Journal of Prevention of Alzheimer's Disease
Publisher
Elsevier BV
Published
2021-10
Volume
8
Issue
4
Pages
513-519
ISSN
2274-5807 (ISSN-L)
OpenAlex
W3174645852
Cited by
41
References
4
FWCI
5.71
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force. https://app.cochat.ai/papers/10.14283/jpad.2021.36
The paper
Kaye, J., Aisen, P., Amariglio, R., Au, R., Ballard, C., Carrillo, M., Fillit, H., Iwatsubo, T., Jimenez-Maggiora, G., Lovestone, S., Natanegara, F., Papp, K., Soto, M. E., Weiner, M., & Vellas, B. (2021). Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.14283/jpad.2021.36

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.